13th International Symposium on Viral Hepatitis and Liver Disease


Aims of the Meeting

To bring together the entire community involved in viral hepatitis research to promote better understanding of the viruses that cause hepatitis in humans, as well as the pathogenesis, natural history, complications, treatment and prevention of the diseases that they cause. A special focus of the meeting will be on interdisciplinary approaches to global control of viral hepatitis through vaccination and public health measures. Another important focus will be on the long-term clinical complications such as chronic hepatitis, cirrhosis and hepatocellular cancer. The meeting will include plenary sessions each morning that provide comprehensive state-of-the-art overviews of the five known human hepatitis viruses: HAV, HEV, HBV, HDV and HCV. Afternoon parallel sessions (4-8 concurrently) will provide a forum for presentation of new findings in the area of both basic and clinical research on viral hepatitis. These presentations will be based upon abstract submissions to the meeting. An electronic-based poster session will be available for the entire meeting. A final session will provide a forum for “late-breaking” advances. Satellite symposia are planned immediately before the meeting, on two evenings and during lunch time periods. The meeting will be sponsored by the National Institutes of Health and the American Association for the Study of Liver Diseases (AASLD) with co-support from the Centers for Disease Control and Prevention, the Food and Drug Administration, the Office of the Surgeon General of the U.S. Public Health Service, and the World Health Organization.


Overcoming, in-vitro, the specific immune suppression during the window period of HCV infection enables the detection of currently missed infected individuals.